Santhera Announces Principal Investigator to Present Phase III Data on Idebenone in Duchenne Muscular Dystrophy (DMD) at the Annual Meeting of the American Academy of Neurology (AAN)
Mika Leinonen (mika.leinonen4pharma.com), Mar 27th 2015Santhera Pharmaceuticals (SIX: SANN) announces that Gunnar M. Buyse, PhD, MD, Professor of Child Neurology at the University Hospitals Leuven (Belgium), and principal investigator, will present outcome data of the Phase III trial with Raxone®/Catena® (idebenone) in Duchenne Muscular Dystrophy (DMD) at the upcoming annual meeting of the American Academy of Neurology (AAN).
The oral presentation titled, "Idebenone Reduces Loss of Respiratory Function in Duchenne Muscular Dystrophy-Outcome of a Phase III Double Blind, Randomised, Placebo controlled Trial (DELOS)," will be held during the Clinical Trials Plenary Session on Friday, April 24, 12:00 pm-1:30 pm. This session was designed by the AAN to address important clinical topics identified throughout the neurology community that affect patient care, and the Science Committee considered the DELOS outcome a critical advancement in the field of neuroscience.
4Pharma felt privileged to be part of the study team and assist Santhera in management, visualization, analysis and reporting of the presented DELOS data.
For more information please visit www.santhera.com.